AMGEN Inc
NASDAQ: AMGN
$293.54
-$4.24 (-1.4%)
Closing Price on February 7, 2025
AMGN Articles
Despite big companies holding unprecedented billions and billions of dollars on their balance sheets, it is shocking how many companies do not reward shareholders in the most classic sense by paying...
Published:
Last Updated:
Earnings season is in full swing and we have a back-breaker of an earnings week ahead of us. There are some 11 DJIA components reporting earnings and a whole slew of other major market-movers and...
Published:
Last Updated:
After about two weeks of being quiet and dark, Wall Street research departments are back after the holidays. These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations...
Published:
Last Updated:
2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer ten-baggers with...
Published:
Last Updated:
These are some of this Wednesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. ABB Ltd. (NYSE: ABB) Raised to Buy at Stern Agee. Akamai Technologies Inc....
Published:
Last Updated:
These are some of this Friday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Raised to Outperform at Leerink Swann. AON...
Published:
Last Updated:
The Battelle Memorial Institute, which looks at R&D in major nations, says that China will pass Japan as the No.2 spender next year. “China is expected to spend $153.7 billion on R&D in...
Published:
Last Updated:
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Raised to Overweight at Piper Jaffray. AT&T Inc....
Published:
Last Updated:
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Neutral at Credit Suisse. AstraZeneca...
Published:
Last Updated:
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally. It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful...
Published:
Earnings season is in full swing and the peak will occur next week. We have several DJIA components reporting earnings along with several other companies which are equally as important to the...
Published:
Last Updated:
Biotech and BioHealth stocks are on the move today and there is more news in the emerging sector than there has been on a single day in months and months. The news is not even on any of the...
Published:
Last Updated:
These are some of this Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls: Amgen Inc. (NASDAQ: AMGN) Started as Buy at Stifel Nicolaus. AngloGold...
Published:
Last Updated:
Genzyme Corporation (NASDAQ: GENZ) still has an incredible merger ‘deal premium’ associated with it over a pending Sanofi-Aventis (NYSE: SNY) buyout. Genzyme’s troubles have left it...
Published:
Last Updated:
Genzyme Corporation (NASDAQ: GENZ) is flying high on reports that Sanofi-Aventis (NYSE: SNY) may have an interest in buying the company. The WSJ reports that the large drug giant has approached...
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.